目的 基于血清藥物化學(xué)技術(shù)對(duì)五酯膠囊中成分和大鼠入血成分進(jìn)行鑒定。方法 采用UPLC-Q-TOF-MS法對(duì)五酯膠囊成分組、給藥組和空白組樣品進(jìn)行分析，通過(guò)MassLynx V4.1軟件對(duì)所得圖譜進(jìn)行數(shù)據(jù)解析，對(duì)五酯膠囊中成分及其入血成分進(jìn)行鑒定。結(jié)果 鑒定出五酯膠囊中15個(gè)化合物，其中五味子甲素含量最高。大鼠血清中含有五酯膠囊2個(gè)原型成分五味子酯丁、長(zhǎng)南酸，篩選得到代謝物8個(gè)，主要以I相代謝反應(yīng)中的水解、氧化、去甲氧基化反應(yīng)和II相代謝反應(yīng)中的葡萄糖醛酸化結(jié)合為主。結(jié)論 建立了五酯膠囊中活性成分和代謝產(chǎn)物的鑒定方法，為五酯膠囊的臨床應(yīng)用提供依據(jù)。

Objective To identify the components in Wuzhi Capsules and rats blood components based on serum pharmacochemistry technology. Methods Samples of ingredients of Wuzhi Capsules group, Wuzhi Capsules group, and blank group were analyzed by UPLC-Q-TOF-MS method. The data were analyzed by MassLynx V4.1 software, and the components in Wuzhi Capsules and rats blood components were identified. Results There were 15 identified components in in Wuzhi Capsules, and the content of schisandrin A was the highest. The serum of rats contained two prototype components in Wushizi Capsules, namely schisantherin D and changnanic acid, and 8 metabolites were screened out. These components were mainly composed of hydrolysis, oxidation, and demethoxylation reaction in phase I metabolic reactions, as well as glucuronidation in phase II metabolic reaction. Conclusion The method can identify active ingredients and metabolites in Wuzhi Capsules, providing a basis for clinical application of Wushizi Capsules.

R286.02

國(guó)家自然科學(xué)基金資助項(xiàng)目（81903938）